• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Natera (NTRA) Is Up 20.3% After Raising 2026 Guidance And Expanding Signatera’s Oncology Reach

    Simply Wall St·08/09/2026 09:36:07
    Listen to the news
    • In early August 2026, Natera reported second-quarter revenue of US$752.75 million with higher testing volumes and narrower losses, raised full-year 2026 revenue guidance to US$2.85 billion–US$2.91 billion, and filed an US$849.22 million shelf registration for 3,200,000 common shares tied to an ESOP offering.
    • At the same time, Natera moved to deepen Signatera’s role in oncology by seeking Japanese approval of the test as a companion diagnostic in muscle-invasive bladder cancer, extending its earlier PMDA clearance in colorectal cancer and adding to recent US FDA and NCCN backing.
    • We will now examine how this upgraded 2026 revenue outlook, supported by expanding Signatera indications, may influence Natera’s broader investment narrative.

    Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

    Natera Investment Narrative Recap

    To own Natera, you need to believe that its high-volume molecular testing model can eventually offset persistent losses and heavy R&D spending, particularly in oncology. Right now, the key near term catalyst is broader clinical and regulatory adoption of Signatera, while the biggest risk is that rising costs and reimbursement pressures keep profitability out of reach. The latest guidance raise and narrower losses support the bull case, but they do not remove that core risk.

    Among the recent announcements, the PMDA filing for Signatera as a companion diagnostic in muscle-invasive bladder cancer in Japan looks most relevant. It builds directly on the earlier Japanese approval in colorectal cancer and US endorsements, which together underpin expectations that oncology testing volumes can remain a primary growth driver. If regulators or payers become more conservative than expected, however, the timing and magnitude of that oncology-led upside could look very different.

    Yet while momentum looks encouraging, investors should be aware that reimbursement shifts or tighter healthcare budgets could still materially affect...

    Read the full narrative on Natera (it's free!)

    Natera's narrative projects $4.2 billion revenue and $300.7 million earnings by 2029.

    Uncover how Natera's forecasts yield a $282.14 fair value, a 12% downside to its current price.

    Exploring Other Perspectives

    NTRA 1-Year Stock Price Chart
    NTRA 1-Year Stock Price Chart

    Some of the lowest ranked analysts were already assuming about 16.8% annual revenue growth and no profits by 2029, reminding you that opinions differ and this new guidance and regulatory progress could easily shift how both the upside and these more cautious expectations are viewed.

    Explore 4 other fair value estimates on Natera - why the stock might be worth over 2x more than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Natera research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
    • Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.

    Curious About Other Options?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.